Bispecific Antibody Constructs Mediate Immunotherapeutic Retargeting
1,337 views
|
March 2, 2016
Chronic viral hepatitis is a major public health threat. Current strategies for eradicating the virus and treating virus-induced liver disease and hepatocellular carcinoma are very limited. Novel therapeutic strategies are in urgent need. Immunotherapeutic retargeting of effector cells is a promising approach to circumvent the immunotolerant state found in malignancies and chronic viral infections. In this webinar Dr. Bohne from the German Research Center for Environmental Health (Helmholtz Zentrum München) will discuss using xCELLigence® RTCA technology in conjunction with other cellular/molecular tools to identify bispecific antibody constructs as a promising new immunetherapeutic approach against chronic hepatitis B. Specific topics covered include:
• An overview of the molecular biology of hepatitis B virus (HBV) infection and strategies for
developing T-cell based therapeutics for viral hepatitis and hepatocellular carcinoma
• The design of tetravalent bispecific antibody constructs
• Use of xCELLigence® RTCA in quantitative assessment of T-cell and antibody-dependent T-cell
mediated cytotoxic elimination of HBV-infected target cells
Dr. Felix Bohne is a group leader within the Institute of Virology at the German Research Center for Environmental Health (Helmholtz Zentrum München). His current research focuses on better understanding the interaction of the hepatitis B (HBV) and C (HCV) viruses with their host, as well as developing new therapeutic strategies to treat chronic viral hepatitis and hepatocellular carcinoma. Dr. Bohne received his Ph.D. in Genetics from the University of Cologne. He then conducted postdoctoral research on the immunology of liver transplantation at the Hospital Clinic of Barcelona. Dr. Bohne subsequently completed a prestigious personal postdoctoral fellowship granted by the Deutsche Forschungsgemeinschaft (DFG) at the Technical University of Munich and at the German Research Center for Environmental Health.
For more information, please visit: http://www.aceabio.com/products/xcelligence-rtca/
